Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630112 | 1.00 | PREP (0.67) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL5525089 | 1.00 | PREP (0.67) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL630096 | 0.96 | FKBP1A (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL3578099 | 0.96 | FKBP1A (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469372 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL19258206 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469393 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469366 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL2769697 | 0.92 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1056362 | 0.92 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866347-B1 | PROPYLENE POLYMER CATALYST DONOR COMPONENT | INEOS TECH USA LLC (US) | 2018-05-09 | — | — | EP | claimed |
| US-20080125614-A1 | Propylene polymer catalyst donor component | INNOVENE USA (US) | 2008-05-29 | — | — | US | claimed |
| EP-1866347-A2 | PROPYLENE POLYMER CATALYST DONOR COMPONENT | INEOS USA LLC (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006110234-A2 | PROPYLENE POLYMER CATALYST DONOR COMPONENT | INEOS USA LLC (US) | 2006-10-19 | — | — | WO | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260015363-A1 | SUBSTITUTED PYRIMIDINE-FUSED RING INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-4950767-A | Process for the preparation of the (-)-antipode of (E)-1-cyclohexyl-4,4-dimethyl-3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-ene | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-21 | — | — | US | disclosed |
| US-4943635-A | OXAZABOROLIDINES AND OXAZABORINES AS CATALYSTS | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1990-07-24 | — | — | US | disclosed |
| US-4837349-A | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0305180-A2 | Enantioselective reduction of ketones | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4808725-A | Process for the preparation of the (-)-antipode of (E)-1-cyclohexyl-4, 4-dimethyl-3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-ene | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-28 | — | — | US | disclosed |
| EP-0237902-A2 | Process for the preparation of the (-)-antipodes of (E)-1-cyclohexyl-4,4-dimethyl-3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-enes | BAYER AG (DE) | 1987-09-23 | — | — | EP | disclosed |
| EP-0217243-A2 | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1987-04-08 | — | — | EP | disclosed |
| EP-0210065-A1 | 6-Alkylidene penems | BEECHAM GROUP PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015363-A1 | SUBSTITUTED PYRIMIDINE-FUSED RING INHIBITOR, METHOD FOR PREPARING SAME, AND USE THEREOF | KRAS, NRAS, HRAS | PREP 2653/4885NPSR1 4424/4885FKBP1A 1841/4885 |
| US-20080125614-A1 | Propylene polymer catalyst donor component | RAD52, PGR, DRD2 | PREP 4133/4885NPSR1 1178/4885FKBP1A 1570/4885 |
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | PREP 983/4885NPSR1 4342/4885FKBP1A 3135/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | PREP 3223/4885NPSR1 4736/4885FKBP1A 2885/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | PREP 4822/4885NPSR1 4652/4885FKBP1A 3288/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | PREP 2676/4885NPSR1 4476/4885FKBP1A 4019/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | PREP 4467/4885NPSR1 4397/4885FKBP1A 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.